Biomea Fusion Corp (BMEA) Cash per Single Share

Biomea Fusion, Inc. - graphic logo of issuer BMEA

The key driver for Biomea Fusion, Inc. (BMEA) is its innovative small-molecule platform, which defines future patents. The development of inhibitors to combat oncology and diabetes amid fierce R&D competition is complemented by complex drug thermologistics. The cash per share calculation demonstrates financial stability, with the metric holding around 0.36, confirming the issuer's liquid reserves.

BMEA - Biomea Cash per Share over the range 07/04/2022 - 11/20/2026

Analytical breakdowns for Biomea Fusion, Inc.

- market value and analyst target forecast:
- cash availability and cash flow indicators:
Summary company analysis:BMEA (Biomea)
Original product of Biomea Fusion

This indicator measures net liquidity per share, stripping out volatility and one-time payments to assess the issuer's actual financial reserve. By analyzing the current cash per share level, an investor determines the balance between solvency and capitalization efficiency, which is critically important for Biomea Fusion, Inc. (BMEA) when financing breakthrough developments in covalent inhibitors for diabetes and oncology therapies.